Company | Directors
Daniel Vapnek, Ph.D.- Chairman
Dr Vapnek has been an advisor to BioArray Solutions since inception of operations in 1997, and a Director since incorporation in 2001, currently serves as Chairman. He also serves, and has served, as Director to private and public biotechnology and device companies, and has been an advisor to several venture funds. Dr Vapnek was Senior Vice President of Research of Amgen from 1988 to 1996, having previously led Amgen's research programs as Vice President and Director of Research. Prior to joining Amgen in 1981, Dr. Vapnek held positions as Assistant Professor, Associate Professor and Professor of Molecular and Population Genetics at the University of Georgia beginning in 1972. Dr. Vapnek received his undergraduate training and, in 1968, obtained his Ph. D. in Microbiology from the University of Miami. He served as a Research Associate and US Public Service Health Service Post-Doctoral Fellow at Yale University's School of Medicine.
R James (“Jim”) Danehy
Jim Danehy brings to his role at BioArray Solutions a wealth of experience reflecting a career of 30+ years in multiple sales, marketing and general management capacities with leading medical device and diagnostic systems companies including: Ventana Medical Systems (VMSI) where, as President and CEO, he led the privately held, venture capital backed company from $4 million in annual sales and $12 million in annual expenditures to $25 million in annual sales and cash flow self-sufficiency in a three year period, successfully completing both an IPO and a Secondary Stock Offering; and Abbott Laboratories where, over a period of twenty years, from 1972 to 1993, he held multiple management positions including: Product Manager for Hepatitis Products; Marketing Manager for TDx Systems; Director of Marketing for the Diagnostics Division; and General Manager Blood Transfusion Diagnostics Business. Jim holds a B.S. in Chemistry from St. Joseph’s College and an MBA from Loyola University of Chicago.
William J. Gedale, J.D.
Mr Gedale,a Managing General Partner of NGN Capital (www.ngncapital.com), has been in the investment business since 1965. Mr. Gedale joined NGN from Mount Everest Advisors, which he founded in 1996. Between 1999 to 2001, he served as an investment advisor to individuals and as a full time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm, and this capacity, he initiated the $140 million dollar financing of ZymoGenetics. He also helped arrange the $350 million funding by Sandoz (Novartis) of the Scripps Research Institute and the $40 million funding of the Neuroscience Institute of La Jolla, California (of which he is a trustee). Before founding Mount Everest Advisors, he was a Managing Director at John W. Bristol & Co. in 1995. Previously, as of 1989, Mr. Gedale was President & Chief Executive Officer of General American Investors, which he joined in 1969. He is currently Chairman of Promosone and Vice Chairman of Enzybiotics. He has been a director of Gamco (Gabelli Holding), General American Investors, Allied Clinical Laboratories, U.S. Home Health Care, Unilab Corporation, and BioReliance Corporation. William Gedale holds an M.B.A. from New York University, a J.D. from Fordham Law School, and an A.B. from Syracuse University.
Yuichi Iwaki, M.D., Ph.D.
Dr. Iwaki holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetics Laboratory since 1992. He is also a visiting professor at the Nihon University School of Medicine, Kyushu University and the Tokyo Women's Medical School in Japan. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. In addition, Dr Iwaki is the Chairman of Medici Nova (www.medicinova.com) , a publicly traded specialty pharmaceutical company in San Diego, CA which is focused on acquiring and accelerating the global development and commercialization of innovative pharmaceutical products. Dr Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of 200 peer-reviewed publications and more than 40 books. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 20 years and is a board member of several biotechnology companies, including Avigen Inc.
Michael Seul, Ph.D.
Michael Seul has led the development of the Company’s BeadChip™ format of complex molecular analysis, and, over the past five years, in close interaction with the Company’s late Chairman, Dr Philip J Whitcome, developed and implemented a strategy of realizing the Company’s integrated BeadChip™ system addressing the practical needs of the diagnostics, drug development and medical research communities. Michael has attracted preeminent experts and biotechnology pioneers as Directors, advisors and collaborators. His expertise in biophysical chemistry and image analysis is reflected in the Company’s broad patent estate. Prior to establishing BioArray Solutions, Michael, during his decade-long tenure at AT&T Bell Laboratories, established an internationally recognized research program with a focus on the physical chemistry of interfaces, membranes and colloidal systems. He also coauthored, with two colleagues, a successful book on “Practical Algorithms for Image Analysis,” published by Cambridge University Press. Michael, as a Rotary Foundation Fellow, attended Stanford University where he received his Ph.D. in Biophysics.
